Biosidus launches new bioreactor plant in Buenos Aires, expanding global supply capacity for agalsidase beta
Executive summary: Biosidus brought online a new bioreactor plant in Buenos Aires, boosting its production capacity for biologics including agalsidase beta. The expansion increases global supply of a key enzyme replacement therapy, potentially alleviating shortages and lowering production costs.
Who is involved: Biosidus (Argentinian biotech company), its manufacturing team, and regulatory bodies overseeing GMP compliance.
Likely next: The company may seek additional regulatory approvals for expanded output and pursue distribution partnerships in Europe and North America.
Biosidus announced that its new bioreactor facility in Buenos Aires is now operational, increasing the company's ability to produce biologics, particularly the enzyme agalsidase beta used in Fabry disease treatment. The expansion aims to strengthen Biosidus's worldwide supply chain and reduce reliance on external manufacturers. The move reflects growing demand for biosimilar and biologic therapies and positions the Argentine biotech firm to capture a larger share of the contract development and manufacturing organization (CDMO) market.
Timeline
- — Biosidus erweitert seine Produktionskapazitäten für Biologika und stärkt seine weltweiten Lieferkapazitaten für Agalsidase beta (PR Newswire)
Analysis — what this means
Sectors affected
- Biologics manufacturing
- Enzyme replacement therapy (agalsidase beta)
- Pharmaceutical supply chain
Key entities
Sources
Open the full interactive case file on Beyond →